A prospective study to assess the safety of MRI at a magnetic field strength of 1.5 Tesla in patients with a pacemaker (58%) or an implantable cardioverter–defibrillator (42%) that was not considered to be MRI-conditional (termed a “legacy” device) showed no long-term clinically significant adverse events. The study included 1509 patients with 2103 thoracic and nonthoracic MRI examinations. The pacing mode was changed to asynchronous mode for pacing-dependent patients and to demand mode for other patients. Tachyarrhythmia functions were disabled. No long-term clinically significant adverse events were reported. In nine MRI examinations (0.4%), the patient’s device reset to a backup mode. The reset was transient in eight of the nine examinations. The most common notable change in device parameters (>50% change from baseline) immediately after MRI was a decrease in P-wave amplitude, which occurred in 1% of the patients. At long-term follow-up (results of which were available for 63% of the patients), the most common notable changes from baseline were decreases in P-wave amplitude (in 4% of the patients); increases of capture threshold in atria (4%), in right ventricle (4%), and in left ventricle (3%), respectively. The observed changes in lead parameters were not clinically significant and did not require device revision or reprogramming. Source: http://www.nejm.org/
A rigorous cohort study utilizing Taiwan’s National Health Insurance Database provides robust evidence that SGLT2…
A new study investigating the link between cerebral microbleeds (CMBs) and dementia has found that…
A comprehensive prospective study tracking over 159,000 adults for up to three decades has provided…
A comprehensive new Cochrane review of 22 studies involving nearly 2,000 participants over six months…
A large-scale study involving 103,649 UK Biobank participants has revealed that adhering to healthy dietary…
To address uncertainties in statin safety profiles, which are often based on observational data susceptible…
This website uses cookies.